Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 2
2018 2
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC. McCoach CE, et al. Clin Cancer Res. 2018 Jul 15;24(14):3334-3347. doi: 10.1158/1078-0432.CCR-17-2452. Epub 2018 Apr 10. Clin Cancer Res. 2018. PMID: 29636358 Free PMC article.
Acquired Resistance Is Oncogene and Drug Agnostic.
Doebele RC. Doebele RC. Cancer Cell. 2019 Oct 14;36(4):347-349. doi: 10.1016/j.ccell.2019.09.011. Cancer Cell. 2019. PMID: 31614114 Free PMC article. Review.
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC. McCoach CE, et al. Clin Cancer Res. 2018 Jun 15;24(12):2758-2770. doi: 10.1158/1078-0432.CCR-17-2588. Epub 2018 Mar 29. Clin Cancer Res. 2018. PMID: 29599410 Free PMC article.
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.
Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC. Vaishnavi A, et al. Cancer Res. 2017 Jul 1;77(13):3551-3563. doi: 10.1158/0008-5472.CAN-17-0109. Epub 2017 Apr 20. Cancer Res. 2017. PMID: 28428274 Free PMC article.
Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Nelson-Taylor SK, Le AT, Yoo M, Schubert L, Mishall KM, Doak A, Varella-Garcia M, Tan AC, Doebele RC. Nelson-Taylor SK, et al. Mol Cancer Ther. 2017 Aug;16(8):1623-1633. doi: 10.1158/1535-7163.MCT-17-0008. Epub 2017 May 12. Mol Cancer Ther. 2017. PMID: 28500237 Free PMC article.
Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.
McCoach CE, Bivona TG, Blakely CM, Doebele RC. McCoach CE, et al. Clin Lung Cancer. 2016 Sep;17(5):466-469. doi: 10.1016/j.cllc.2016.05.025. Epub 2016 Jun 8. Clin Lung Cancer. 2016. PMID: 27378174 Free PMC article.
Feedback